Journal of cardiovascular electrophysiology · 2025
Safety and Clinical Outcome of Subcutaneous Implantable Cardioverter-Defibrillators in an Asian Population: A Prospective Study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Karen Ka Ying, Ching Chi Keong, Hussin Azlan, Ngarmukos Tachapong, Chan Joseph Y S, Joung Bo-Young, Shoda Morio, Hua Wei, Ngan Abe Ho Ting, Tse Hung-Fat
Аннотация
BACKGROUND: There is limited data on long-term safety and efficacy of subcutaneous implantable cardioverter defibrillator (S-ICD) in Asian patients with a lower body mass index (BMI) due to smaller body build.
METHODS: We performed a 2 year prospective study in 5 Asian cities from May 2017 to May 2018 to investigate the safety and feasibility of S-ICD for primary or secondary prevention of sudden cardiac death in an Asian population.
RESULTS: We enrolled 75 S-ICD recipients (77% males; age 49.6 ± 16.8 years) with a mean BMI of 24.6 ± 5.0 (range 15.9-40.9) with 67% (50/75) with BMI ≤ 23. The indications of S-ICD were primary and secondary prevention in 26 (35%) and 49 (65%) patients, respectively. Among them, 51 patients suffer from ischemic (30, 59%) or nonischemic (21, 41%) cardiomyopathy, and 25 patients have channelopathies. Their mean left ventricular ejection fraction was 44.4 ± 15.1%. All patients had successful S-ICD implantation with a mean procedural duration of 75.5 ± 28.1 min using conscious sedation in majority of patients (65/75, 87%); and defibrillation testing was performed in 62 patients (83%). After 2 years of follow-up, 8 patients developed serious adverse events, including 4 deaths (2 asystole, 1 sepsis, 1 myocardial infarction), 2 ventricular tachycardia storm, 1 pocket infection, and 1 lead failure requiring replacement. Both patients with ventricular tachycardia storm received appropriate shocks, and no patient developed inappropriate shocks.
CONCLUSIONS: S-ICD implantation for both primary and secondary prevention of sudden cardiac death was found to be safe in an Asian population, including those with a low BMI, and was associated with a low rate of device-related complications.
METHODS: We performed a 2 year prospective study in 5 Asian cities from May 2017 to May 2018 to investigate the safety and feasibility of S-ICD for primary or secondary prevention of sudden cardiac death in an Asian population.
RESULTS: We enrolled 75 S-ICD recipients (77% males; age 49.6 ± 16.8 years) with a mean BMI of 24.6 ± 5.0 (range 15.9-40.9) with 67% (50/75) with BMI ≤ 23. The indications of S-ICD were primary and secondary prevention in 26 (35%) and 49 (65%) patients, respectively. Among them, 51 patients suffer from ischemic (30, 59%) or nonischemic (21, 41%) cardiomyopathy, and 25 patients have channelopathies. Their mean left ventricular ejection fraction was 44.4 ± 15.1%. All patients had successful S-ICD implantation with a mean procedural duration of 75.5 ± 28.1 min using conscious sedation in majority of patients (65/75, 87%); and defibrillation testing was performed in 62 patients (83%). After 2 years of follow-up, 8 patients developed serious adverse events, including 4 deaths (2 asystole, 1 sepsis, 1 myocardial infarction), 2 ventricular tachycardia storm, 1 pocket infection, and 1 lead failure requiring replacement. Both patients with ventricular tachycardia storm received appropriate shocks, and no patient developed inappropriate shocks.
CONCLUSIONS: S-ICD implantation for both primary and secondary prevention of sudden cardiac death was found to be safe in an Asian population, including those with a low BMI, and was associated with a low rate of device-related complications.